![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Janssen’s Treatment for Adults with Schizophrenia
FDA Approves Janssen’s Treatment for Adults with Schizophrenia
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
Johnson & Johnson’s Janssen subsidiary has won FDA approval for Invega Hafyera (6-month paliperidone palmitate) as a twice-a-year injectable treatment for adults with schizophrenia.
Before receiving the treatment, patients must first be treated with Invega Sustenna, a once-a-month injection, for at least four months, or with Invega Trinza, a 3-month injection, for at least one cycle.
The approval was supported by results from a late-stage study in 702-participants in which 92.5 percent of patients treated with Invega Hafyera were relapse-free after a year.
Upcoming Events
-
21Oct